UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 17, 2008
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 0-26224 51-0317849
(State or other Jurisdiction of (Commission File Number) IRS Employer
incorporation or organization) Identification No.)
311 Enterprise Drive
Plainsboro, NJ 08536
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (609) 275-0500
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
===============================================================================
ITEM 8.01 OTHER INFORMATION
Integra LifeSciences Holdings Corporation (the "Company") was unable to file its
Annual Report on Form 10-K for the year ended December 31, 2007 (the "Form
10-K") by the extended filing date under Rule 12b-25 of the Securities Exchange
Act of 1934, as amended, due to its ongoing review and approval of certain
account reconciliations, the Company's tax provision for the fourth quarter and
year ended December 31, 2007, and deferred tax balance sheet accounts, as
disclosed in the Notification of Late Filing on Form 12b-25 that the Company
filed with the Securities and Exchange Commission on February 29, 2008.
The Company intends to file the Form 10-K as soon as practicable after the
completion of its audited financial statements for the year ended December 31,
2007.
Statements in this Current Report on Form 8-K may be forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 that
involve risks, uncertainties and reflect the Company's judgment as of the date
of this report. Such forward-looking statements include, but are not limited to,
the Company's ability to complete the financial statements for the fourth
quarter and 2007 fiscal year in a timely manner; the Company's ability to file
its Annual Report on Form 10-K for year ended December 31, 2007; and the
expectations, plans and prospects for the Company. Such forward looking
statements involve risks and uncertainties that could cause actual results to
differ materially from predicted or expected results, including, without
limitation, unanticipated accounting issues regarding financial data with
respect to account reconciliations, the tax provision, and deferred tax balance
sheet accounts; market conditions and other factors beyond the Company's control
and the economic, competitive, governmental, technological and other factors
identified under the heading "Risk Factors" included in item IA of the Company's
Annual Report on Form 10-K for the year ended December 31, 2006, and information
contained in subsequent filings with the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
Date: March 17, 2008 By: /s/ John B. Henneman, III
----------------------------------
John B. Henneman, III
Executive Vice President,
Chief Administrative Officer
and Acting Chief Financial Officer